Drug Profile
Research programme: Parkinson's disease therapeutics - Alnylam Pharmaceuticals/Mayo Clinic
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Mayo Clinic
- Class Small interfering RNA
- Mechanism of Action Alpha-synuclein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (Intracerebral, Injection)
- 05 Nov 2008 Interim pharmacodynamics and safety data from a preclinical trial in a mouse model of Parkinson's disease released by Alnylam Pharmaceuticals
- 05 Jan 2008 Alnylam Pharmaceuticals, the Mayo Clinic, and the Parkinson's Institute and Clinical Center receive a grant from the Michael J. Fox Foundation for development of therapeutics targeting alpha-synuclein for Parkinson's disease